Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast